Biotech | September 03, 2021
Omeza Collegen Matrix gets U.S. FDA approval
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The company has been sold to Shinshin Pharmaceuticals
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
The drug is also intended for the treatment of glioblastoma multiforme
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The segment delivered strong sales growth of 20% YoY
Subscribe To Our Newsletter & Stay Updated
